Sign up for our FREE GI E-Weekly for more coverage like this sent to your inbox!
Sinopharm has agreed to purchase and distribute at least $3.85 million of the company’s SRS II Systems.
SRS II Systems are designed to be used as a minimally invasive treatment for Gastroesophageal Reflux Disease.
More Articles on Gastroenterology:
Dr. Nanda Kerkar Joins Children’s Hospital LA
Study Shows Accuracy of Optical Biopsy Over Traditional Endoscopy
First Alabama Pediatric Colorectal Clinic Opens
